HS 300390 covers a broad range of bulk medicaments excluding antibiotics, hormones, and alkaloids, primarily traded in pre-retail pharmaceutical supply chains. India and China dominate global supply as leading API and formulation manufacturers, making country of origin verification critical for regulatory compliance under FDA, EMA, and equivalent frameworks. Demand is structurally inelastic due to therapeutic necessity, but supply chain disruptions—particularly API sourcing from concentrated Asian markets—represent a key risk factor for importers.
HS Code 300390 covers Bulk Pharmaceutical Compounds (Non-Antibiotic/Non-Hormonal) under the Harmonized System. It is used for customs declarations, import duty assessment, trade statistics, export documentation, and sourcing analysis.
Products classified under HS 300390 are used across Hospitals, Pharmaceutical Manufacturers, Compounding Pharmacies, Research Institutions. Demand is driven by Aging population, Chronic disease prevalence, Healthcare expenditure growth, Generic drug manufacturing expansion.
Major exporting countries include Portugal, United States, Switzerland, Germany, Belgium based on recent international trade reporting.
Demand is linked to Aging population, Chronic disease prevalence, Healthcare expenditure growth, Generic drug manufacturing expansion. Input costs are influenced by Active Pharmaceutical Ingredients (APIs).
Verify final rates with HTSUS, TARIC, CBIC India, and a licensed customs broker.
US importers of Bulk Pharmaceutical Compounds (Non-Antibiotic/Non-Hormonal) must classify at the HTS10 level. Additional measures such as Section 232, Section 301, ADD/CVD, or Chapter 99 provisions may apply depending on the exact classification and origin.
EU importers classify Bulk Pharmaceutical Compounds (Non-Antibiotic/Non-Hormonal) at TARIC10 level. Preferential treatment may apply where rules of origin are satisfied under EU trade agreements. Intra-EU trade is duty-free.
India assesses Bulk Pharmaceutical Compounds (Non-Antibiotic/Non-Hormonal) at the HS8 level under the CBIC Customs Tariff. The applicable duty framework is: BCD 10% + SWS 1% + IGST 5% = 16.66% effective gross rate. IGST is generally recoverable for registered B2B importers via GST filing.
Based on recent international trade data, the leading exporting countries for Bulk Pharmaceutical Compounds (Non-Antibiotic/Non-Hormonal) are:
These corridors show where trade activity is concentrated. Buyers use this signal to identify supplier depth, established logistics lanes, and alternative sourcing markets.
| HS Code | 300390 |
| Product | Bulk Pharmaceutical Compounds (Non-Antibiotic/Non-Hormonal) |
| Chapter | 30 — Pharmaceutical |
| Major exporting countries | Portugal, United States, Switzerland, Germany, Belgium |
| Primary industries | Hospitals, Pharmaceutical Manufacturers, Compounding Pharmacies, Research Institutions |
| Trade year | 2024 |
| US duty framework | HTS10 classification dependent |
| EU duty framework | TARIC10 classification dependent |
| India BCD | 10% BCD |
Logitality sourcing intelligence for HS 300390 combines global trade corridors, tariff data, commodity cost signals, FX movement, and supplier-country analysis to compare origins by estimated landed cost.
Compare supplier countries for HS 300390 by full duty stack and landed cost.
Run sourcing intelligence →Read the detailed sourcing guide for HS 300390 Bulk Pharmaceutical Compounds (Non-Antibiotic/Non-Hormonal), including supplier-country analysis, trade-flow context, and procurement considerations.
HS Code 300390 covers Bulk Pharmaceutical Compounds (Non-Antibiotic/Non-Hormonal) and is used for customs declarations, trade statistics, import duty assessment, and sourcing analysis.
Duty varies by destination and classification. US: HTS10 classification dependent. EU: TARIC10 classification dependent. India: 10% BCD.
Major exporting countries include Portugal, United States, Switzerland, Germany, Belgium, based on recent trade reporting.